Phase 2 study comparing the efficacy between afatinib & osimertinib based on immunological biomarker in EGFR-mutant NSCLC

被引：0
|
作者：
Morikawa, Kei [1 ]
Tanaka, Hisashi [2 ]
Takata, Saori [3 ]
Watanabe, Satoshi [4 ]
Kishi, Kazuma [5 ]
Soejima, Kenzo [6 ]
Kaira, Kyoichi [7 ]
Kagamu, Hiroshi [7 ]
Yoshimura, Kenichi [8 ]
Matsutani, Noriyuki [9 ]
Seki, Nobuhiko [10 ]
机构：
[1] St Marianna Univ, Sch Med, Dept Internal Med, Div Resp Med, Kawasaki, Kanagawa, Japan
[2] Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki, Aomori, Japan
[3] Kyorin Univ, Dept Resp Med, Sch Med, Mitaka, Tokyo, Japan
[4] Niigata Univ, Grad Sch Med & Dent Sci, Dept Resp Med & Infect Dis, Niigata, Japan
[5] Toho Univ, Omori Med Ctr, Dept Resp Med, Tokyo, Japan
[6] Keio Univ Hosp, Clin & Translat Res Ctr, Tokyo, Japan
[7] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Moroyama, Saitama, Japan
[8] Hiroshima Univ Hosp, Med Ctr Translat & Clin Res, Hiroshima, Japan
[9] Teikyo Univ Hosp, Dept Surg, Mizonokuchi, Japan
[10] Teikyo Univ, Sch Med, Dept Internal Med, Div Med Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P68-3
引用
收藏
页码：S538 / S538
页数：1
相关论文
共 50 条
  • [41] INSIGHT2: Tepotinib plus osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp
    Morise, Masahiro
    Sakai, Hiroshi
    Kato, Terufumi
    Tokito, Takaaki
    Takeda, Masayuki
    Tanaka, Hiroshi
    Chikamori, Kenichi
    Daga, Haruko
    Kijima, Takashi
    Ohashi, Kadoaki
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    ANNALS OF ONCOLOGY, 2021, 32 : S309 - S309
  • [42] An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in TKI-Naive EGFR-Mutant Metastatic NSCLC
    Le, X.
    Zhu, V.
    Saltos, A.
    Nikolinakos, P.
    Mileham, K.
    Velcheti, V.
    Husain, H.
    Nilsson, M.
    Tran, H.
    Roarty, E.
    Kim, E.
    Ou, S.
    Sanborn, R.
    Gray, J. E.
    Wong, K.
    Hanna, N.
    Papadimitrakopoulou, V.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S838 - S838
  • [43] INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
    Yang, J. C-H.
    Ellers-Lenz, B.
    Straub, J.
    Johne, A.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.
    Yu, Helena Alexandra
    Kim, Rachel
    Makhnin, Alex
    Ahn, Linda Su Hyun
    Ni, Ai
    Hayes, Sara A.
    Young, Robert J.
    Riely, Gregory J.
    Kris, Mark G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)
    Elamin, Y. Y.
    Antonoff, M.
    Blakely, C.
    Baggstorm, M.
    Bivona, T.
    Le, X.
    Louie, A. V.
    Doebele, R. C.
    Rusthoven, C.
    Lee, P.
    Govindan, R.
    Swisher, S. G.
    Papadimitrakopoulou, V. A.
    Heymach, J. V.
    Gomez, D. R.
    ANNALS OF ONCOLOGY, 2018, 29 : 547 - 547
  • [46] Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
    Ramalingam, Suresh S.
    Saka, Hideo
    Ahn, Myung-Ju
    Yu, Helena
    Horn, Leora
    Hida, Toyoaki
    Cantarini, Mireille
    Verheijen, Remy
    Wessen, Jonathan
    Oxnard, Geoffrey
    Ohe, Yuichiro
    CANCER RESEARCH, 2019, 79 (13)
  • [47] A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers.
    Yu, Helena Alexandra
    Hayes, Sara A.
    Young, Robert J.
    Ni, Ai
    Rodriguez, Christopher
    Makhnin, Alex
    Riely, Gregory J.
    Kris, Mark G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutant NSCLC with brain metastases: A dynamic ctDNA-guided study
    Wei, Fang
    An, Juan
    Hua, Yichun
    Ding, Xiaosheng
    Sun, Shibin
    Li, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] A Phase 2 Trial Assessing Osimertinib Activity Against Leptomeningeal Carcinomatosis in EGFR-Mutant Lung Cancer
    Akazawa, Y.
    Nanjo, S.
    Tamiya, M.
    Hata, A.
    Yamaguchi, T.
    Kumagai, T.
    Mori, M.
    Katakami, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S918 - S918
  • [50] A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis
    Park, J. S.
    Hong, M. H.
    Cho, B. C.
    Kim, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1847 - S1847
12345